Sixty-six patients with advanced solid tumors were treated with 4'-epi-doxorubicin at a dose of 90 mg/m2 by rapid IV injection every 21 days until the disease had progressed or to a maximum cumulative dose of 540 mg/m2. Myelosuppression, nausea and vomiting, and alopecia were the almost frequent side effects, but their incidence seemed lower than that after a comparable dosage of doxorubicin. After a cumulative dose of 540 mg/m2 a significant decrease of QRS complex deflection on the electrocardiogram was detected, but no case of congestive heart failure was observed. Partial remission and minor remission were achieved, respectively, in nine (15%) and five (9%) out of 59 evaluable patients for a median duration of 6 months. Partial remission occurred in anthracycline-sensitive tumors like breast cancer (4 of 13), lung cancer (1 of 17), head and neck cancer (1 of 8), gastric cancer (2 of 4), and ovarian cancer (1 of 1).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/BF00256541 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Devil Is in the Details: Pitfalls and Ambiguities in the Analysis of X-ray Powder Diffraction Data of 2D Covalent Organic Frameworks.
JACS Au
January 2025
Max Planck Institute for Solid State Research, Heisenbergstrasse 1, 70569 Stuttgart, Germany.
X-ray powder diffraction (XRPD) data of covalent organic frameworks (COFs) seem to be simple and apparently do not contain a lot of structural information, as these patterns usually do not show more than 3-5 distinguishable Bragg peaks. As COFs are inherently complex materials exhibiting a variety of disorder phenomena like stacking faults, layer curving, or disordered solvent molecules populating the pores, the interpretation of XRPD patterns is far from being trivial. Here we emphasize the critical need for precision and caution in XRPD data acquisition, refinement, and interpretation to avoid common pitfalls and overinterpretations in data analysis.
View Article and Find Full Text PDFReinforcing Bulk Heterojunction Morphology through Side Chain-Engineered Pyrrolopyrrole-1,3-dione Polymeric Donors for Nonfullerene Organic Solar Cells.
ACS Appl Energy Mater
January 2025
School of Advanced Materials Science and Engineering, Sungkyunkwan University (SKKU), Suwon 16419, Republic of Korea.
Organic solar cells (OSCs) are attracting significant attention due to their low cost, lightweight, and flexible nature. The introduction of nonfullerene acceptors (NFAs) has propelled OSC development into a transformative era. However, the limited availability of wide band gap polymer donors for NFAs poses a critical challenge, hindering further advancements.
View Article and Find Full Text PDFTunable structural rearrangement in Cu cluster assemblies through linker and solvent alterations.
Chem Sci
January 2025
Research Institute for Science & Technology, Tokyo University of Science Tokyo 162-8601 Japan
The scarcity of approaches to assembling copper nanoclusters (Cu NCs) has restricted advancements in Cu NCs research, largely due to stability challenges of the individual NCs. By utilizing the structural adaptability of Cu NCs, we systematically investigate how variations in organic linkers and solvents affect the cluster node size, shape, and their assembling dimensionality. Here, we introduce a facile, one-pot synthesis method for obtaining a range of crystalline Cu cluster-assembled materials (CAMs) through a liquid-liquid interfacial crystallization technique.
View Article and Find Full Text PDFObjective: Our objective of this study was to analyse all oncological clinical trials using regorafenib to create a complete risk/benefit profile for the drug.
Background: Creating a novel chemotherapy is costly both in time and capital spent for drug manufacturers. To regenerate what they've spent, drug manufacturers may attempt to repurpose their medications for new indications via clinical trials.
First-in-human phase 1 study of the arginase inhibitor INCB001158 alone or combined with pembrolizumab in patients with advanced or metastatic solid tumours.
BMJ Oncol
May 2024
Sarah Cannon Cancer Institute, Nashville, Tennessee, USA.
Objective: The arginase inhibitor INCB001158 was evaluated for safety (primary endpoint) in locally advanced or metastatic solid tumours; pharmacokinetics, pharmacodynamics and efficacy were also assessed.
Methods And Analysis: In this non-randomised, open-label, three-part phase 1 study, INCB001158 was orally administered two times per day as monotherapy or in combination with intravenous pembrolizumab 200 mg every 3 weeks. Dose expansion was conducted in tumour-type cohorts (with or without prior anti-PD-1/PD-L1 (programmed death protein 1/programmed death ligand 1) therapy).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!